# Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

> **NCT06888232** · NA · COMPLETED · sponsor: **Muhammad Aamir Latif** · enrollment: 121 (actual)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT06888232
- **Lead sponsor:** Muhammad Aamir Latif
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888232, "Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06888232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*